Key Findings: Fate Therapeutics to Present Preliminary Clinical Data for FT819 in Systemic Sclerosis at ISSCR 2026
Fate Therapeutics has announced its intention to present preliminary clinical data for ‘FT819,’ its investigational iPSC (induced Pluripotent Stem Cell)-derived ‘off-the-shelf’ CAR T-cell candidate for systemic sclerosis (SSc), at the 2026 annual meeting of the International Society for Stem Cell Research (ISSCR). This presentation will be based on data from a clinical trial evaluating the safety and preliminary efficacy of FT819 in a treatment-resistant SSc patient population. This marks a significant milestone, demonstrating the potential for iPSC-based cell therapies to extend beyond cancer into new therapeutic areas such as autoimmune diseases, holding promise for a paradigm shift in SSc treatment.
Technical & Clinical Details: Applying iPSC-Derived Off-the-Shelf CAR T-Cells to SSc
FT819 is being developed as a universal CAR T-cell product that can be mass-produced from a single iPSC master cell line, designed as an ‘off-the-shelf’ therapy eliminating the need for donor matching. SSc is a chronic autoimmune disease characterized by fibrosis of the skin, blood vessels, and internal organs, with current treatments often struggling to completely halt disease progression. FT819 aims to suppress disease activity and reduce organ damage by targeting specific cells involved in SSc pathogenesis (e.g., B cells or immune cells promoting fibrosis). The upcoming ISSCR presentation is expected to reveal data on FT819’s safety profile in SSc patients, as well as preliminary effects on disease activity markers and clinical symptoms. iPSC-derived CAR T-cells are anticipated to offer advantages over conventional autologous CAR T-cells in terms of manufacturing efficiency, quality consistency, and cost reduction.
Background & Industry Context: Expanding CAR T-Cell Therapy in Autoimmune Diseases
While CAR T-cell therapy initially showed remarkable therapeutic success in certain hematologic cancers, its application has recently expanded to severe autoimmune diseases. Intractable autoimmune diseases like SSc have limited effective treatment options, and patients suffer from prolonged disease activity and associated organ damage. The concept of CAR T-cell therapy in autoimmune diseases is to address the root cause of the disease by specifically eliminating pathogenic autoreactive lymphocytes, potentially inducing long-term remission. Fate Therapeutics is actively developing off-the-shelf cell therapies for both cancer and autoimmune diseases using iPSC technology, reinforcing its leadership in this field. This upcoming presentation holds the potential to open new avenues for SSc treatment and is generating significant interest from the medical community and patient advocacy groups.
Strategic Significance & Outlook: Transforming SSc Treatment and Diverse iPSC Platform Applications
The presentation of preliminary clinical data for FT819 at ISSCR 2026 will bring new hope to SSc patients and suggests the potential to fundamentally transform existing treatment paradigms. If favorable data is presented, FT819’s development as a breakthrough therapy for SSc will likely accelerate. Furthermore, this success would validate Fate Therapeutics’ iPSC-derived off-the-shelf cell therapy platform as effective not only for cancer therapeutics but also for generating diverse autoimmune disease treatments. Moving forward, the company is expected to further advance FT819’s clinical development and also focus on discovering and developing other iPSC-based autoimmune disease therapy candidates. Further advancements in this field hold critical significance for improving the quality of life for patients suffering from intractable diseases.
Source: #
Get our weekly technology intelligence — free
Receive an infographic that lets you judge at a glance whether each field’s analysis report is worth reading.
Subscribe Free — Weekly Tech Intelligence
By subscribing, you’ll receive Troy-Technical’s weekly technology intelligence newsletter.
- Your email and selected fields are used only to deliver the newsletter.
- We never share your information with third parties.
- You can unsubscribe anytime via the link in each email.
See our Privacy Policy for details.
Takes about a minute · Unsubscribe anytime
Comments